NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: NG-nitro-L-arginine may stop the growth of tumor cells by disrupting blood flow to
the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of NG-nitro-L-arginine
in treating patients with advanced solid tumors.